

Form 51-102F3
Material Change Report

Section 7.1 of National Instrument 51-102
Continuous Disclosure Obligations

Item 1 Name and Address of Company

Friday Night Inc.
105 – 45655 Tamihi Way
Chilliwack, BC, V2R 2M3

Item 2 Dates of Material Change

December 6, 2017

Item 3 News Release

A news release relating to the material change was disseminated via FSCwire on December 6, 2018. The news release has also been filed on the System for Electronic Document Analysis and Retrieval (“SEDAR”) and is available at www.sedar.com.

Item 4 Summary of Material Change

Friday Night Inc. (the Company or Friday Night) announced that Alternative Medicine Association (“AMA”) signed a production contract to produce high-grade concentrates for a major dispensary chain in Nevada.

Item 5 Full Description of Material Change

Friday Night Inc. (the Company or Friday Night) announced that Alternative Medicine Association (“AMA”) signed a production contract to produce high-grade concentrates for a major dispensary chain in Nevada.

The contract specifies:

- The Nevada dispensary chain will supply trim as the raw material to AMA, who will then extract and process the materials into high grade concentrates
- The dispensary will provide a minimum of 100 pounds of trim each month to AMA
- The raw material is subject to third party testing to ensure only the highest quality ingredients are used to make the finished concentrates
- AMA estimates they will produce over 20,000 half-gram units every month

The finished products will be packaged and co-branded with AMA branding.

The first batch of raw material (trim) has been delivered to AMA, weighed more than 150 pounds and tested showing excellent results. The Company will hire at least two more packagers and increase its number of employees on the late shift to meet this growing demand for concentrates.

Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7 Omitted Information

Not Applicable.

Item 8 Executive Officer

Brayden Sutton, President & CEO
604-674-4756 (ext. 1)

Item 9 Date of Report

July 26, 2018.